DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Assistance Listing Number: 93.356]

Announcement of the Intent To Award Single-Source Grants (Multiple Recipients) for Necessary Expenses Directly Related to the Consequences of Hurricanes Fiona and Ian

AGENCY: Office of Head Start (OHS), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Notice of Issuance of Single-Source awards (multiple recipients).

SUMMARY: ACF/OHS announces its intent to award multiple single-source grants totaling $143,436,162 to select organizations operating a Head Start grant in Florida, South Carolina, and Puerto Rico who demonstrated Head Start services in the affective areas were either disrupted or impacted by Hurricanes Fiona and Ian. These awards are for necessary expenses directly related to the consequences of Hurricanes Fiona and Ian, including replacement of damaged or destroyed property and facilities, and increased mental health support.

DATES: All funds must be expended by recipients within 36 months of their award date.

FOR FURTHER INFORMATION CONTACT: Shawna Pinckney, Acting Deputy Director, Office of Head Start, 330 C Street SW, Washington, DC 20201. Telephone: 1–866–763–6481, email: *HeadStart@eclkc.info.*

SUPPLEMENTARY INFORMATION: The Consolidated Appropriations Act, 2023 (H.R. 2617), was signed into law on December 29, 2022. The Act provides $345,000,000 in emergency funding ''for necessary expenses directly related to the consequences of Hurricanes Fiona and Ian, including activities authorized under section 319(a) of the Public Health Service Act.'' Grants were effective starting November 1, 2023, and grant funds will continue to be distributed until September 30, 2027, or until the funding is exhausted.

OHS announces the intent to award the following single-source award (for multiple recipients):

Recipient	Award amount
Children First	$618,209
Wateree Community Action	432,038
Wateree Community Action	362,038
Fundacion Para El Desarrollo De Hogar Propio Incorporado (F.D.H.P.)	3,794,815
Municipality of Humacao	388,508
Fundacion Para El Desarrollo De Hogar Propio Incorporado (F.D.H.P.)	100,000
Municipality of Bayamon	1,603,600
Mid Florida Community Services	26,361,394
Md Florida Community Services	122,704
Municipality of Carolina	17,681,107
Children First	951,033
Municipality of Humacao	1,564,999
Municipality of Guayama	1,458,192
Municipality of Ponce	945,000
Municipality of Guayama	2,808,818
Red por los Derechos de la Ninezyla Juventude Puerto Rico	1,066,441
Municipality of Carolina	13,657,254
Fundacion Para El Desarrollo De Hogar Propio Incorporado (F.D.H.P.)	636,000
Municipality of Isabela	1,707,919
Red por los Derechos de la Ninezyla Juventude Puerto Rico	22,662,122
Municipality of Humacao	2,482,572
Municipality of Orocovis	4,556,732
Wateree Community Action	1,376,510
Municipality of Yabuacoa	480,000
Quintana Baptist Church Head Start Program	2,104,916
Chesterfield Marlboro County Economic Opportunity Council, Inc	1,704,981
Municipality of Guaynabo	2,051,700
Municipality of Dorado	532,631
Municipality of Guayama	90,000
Municipality of Adjuntas	701,120
Municipality of Patillas	169,700
Mid Florida Community Services	303,312
New York Foundling	5,615,651
East Coast Migrant	364,362
Municipality of Quebradillas	996,702
Chesterfield Marlboro County Economic Opportunity Council, Inc	16,994,723
Municipality of Guayama	3,978,361
Children First	9,998
Total	143,436,162

Statutory Authority: The Consolidated Appropriations Act, 2023 (H.R. 2617).

Elizabeth Leo,

Grants Policy Branch Chief, Office of Grants Policy, Office of Administration.

[FR Doc. 2026–15413 Filed 7–29–26; 8:45 am]

BILLING CODE 4184–40–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–7896]

Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).

DATES: These fees apply to the period from October 1, 2026, and will remain in effect through September 30, 2027.

FOR FURTHER INFORMATION CONTACT: *For questions related to FSMA program fees: FSMAFeeStaff@fda.hhs.gov. For questions related to this notice:* Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 301–796–7900; or *FDAUserFees@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Background

Section 743 of the FD&C Act (21 U.S.C. 379j–31) authorizes FDA to assess and collect fees from, in part: (1) the responsible party for each domestic facility and the U.S. agent for each foreign facility subject to a reinspection to cover reinspection-related costs; (2) the responsible party for a domestic facility and an importer who does not comply with a recall order to cover food recall activities associated with such order; and (3) each importer subject to a reinspection to cover reinspection-related costs (sections 743(a)(1)(A), (B), and (D) of the FD&C Act). Section 743 of the FD&C Act directs FDA to establish fees for each of these activities based on an estimate of 100 percent of the costs of each activity for each year (sections 743(b)(2)(A)(i), (ii), and (iv) of the FD&C Act), and these fees must be made available solely to pay for the costs of each activity for which the fee was incurred (section 743(b)(3) of the FD&C Act). These fees are effective on October 1, 2026, and will remain in effect through September 30, 2027.

In section 743(b)(2)(B)(iii) of the FD&C Act, Congress directed FDA to develop a proposed set of guidelines in consideration of the burden of fee amounts on small businesses. FDA issued guidance on this subject in October 2011 (2011 Fee Provision Guidance) (FDA Guidance for Industry, ''Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act'' (October 2011)). As stated in our 2011 Fee Provision Guidance, FDA recognizes that the full cost recovery of FDA reinspection or recall oversight could impose severe economic hardship for small businesses (id.). Therefore, as the 2011 Fee Provision Guidance explains, FDA intends to consider reducing certain fees for those firms (id.). Consistent with the 2011 Fee Provision Guidance, FDA does not intend to issue invoices for reinspection or recall order fees until FDA publishes a separate guidance document outlining the process through which firms may request a reduction in fees.

In addition, as stated in the 2011 Fee Provision Guidance, FDA is considering various issues associated with the assessment and collection of importer reinspection fees. The fee rates set forth in this notice will be used to determine any importer reinspection fees assessed in FY 2027.

II. Estimating the Average Cost of a Supported Direct FDA Work Hour for FY 2027

FDA estimates 100 percent of its costs for each activity to establish fee rates for FY 2027 (see section 743(b)(2)(A) of the FD&C Act).

A. Estimating the Full Cost per Direct Work Hour in FY 2027

Full-time Equivalent (FTE) reflects the total number of regular straight-time hours—not including overtime or holiday hours—worked by employees, divided by the number of compensable hours applicable to each fiscal year. Annual leave, sick leave, compensatory time off, and other approved leave categories are considered ''hours worked'' for purposes of defining FTE employment.

In general, the starting point for estimating the full cost per direct work hour is to estimate the cost of an FTE or paid staff year. Calculating an FDA-wide total cost per FTE requires three primary cost elements: payroll, nonpayroll, and rent.

We used an average of past year cost elements to predict the FY 2027 cost. The FY 2027 FDA-wide average cost for payroll (salaries and benefits) is $244,029; non-payroll (including equipment, supplies, IT, general and administrative overhead) is $108,488; and rent (including cost allocation analysis and adjustments for other rent and rent-related costs) is $24,118 per paid staff year, excluding travel costs.

Summing the average cost of an FTE for payroll, nonpayroll, and rent, brings the FY 2027 average fully supported cost to $376,635 (total includes rounding) per FTE, excluding travel costs. FDA will use this base unit fee in determining the hourly fee rate for reinspection and recall order fees for FY 2027 before including domestic or foreign travel costs as applicable for the activity.

To calculate an hourly rate, we divide the FY 2027 average fully supported cost of $376,635 per FTE by the average number of supported direct FDA work hours in FY 2025 (the last fiscal year for which data are available). See table 1.

TABLE 1—SUPPORTED DIRECT FDA WORK HOURS IN A PAID STAFF YEAR IN FY 2025

Total number of hours in a paid staff year	2,080
Less:	
11 paid holidays	−88
20 days of annual leave	−160
10 days of sick leave	−80
12.5 days of training	−100
22 days of general administration	−176
26.5 days of travel	−212
2 hours of meetings per week	−104